Shattuck Labs reported a net loss of $13.7 million for the first quarter ended March 31, 2025, a decrease from the $18.5 million loss in the same period of 2024. This represents a narrowed loss of 26% year-over-year, with a loss per share of $0.27 compared to $0.37 in Q1 2024.
Research and development expenses decreased by $6.3 million, or 39%, to $9.9 million, primarily due to the discontinuation of the SL-172154 program and related oncology projects. General and administrative expenses also saw a reduction of $0.4 million, or 8.7%, to $4.5 million.
As of March 31, 2025, the company held approximately $60.9 million in cash and cash equivalents, which is expected to fund operations into 2027. All IND-enabling activities and regulatory interactions for SL-325 remain on track for a Phase 1 clinical trial initiation in the third quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.